-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
IceCure Medical (NASDAQ:ICCM) Stock Price Down 3%
IceCure Medical (NASDAQ:ICCM) Stock Price Down 3%
IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) shares fell 3% during mid-day trading on Monday . The company traded as low as $1.30 and last traded at $1.30. 137,650 shares traded hands during trading, a decline of 76% from the average session volume of 566,353 shares. The stock had previously closed at $1.34.
Analyst Ratings Changes
Separately, Maxim Group began coverage on IceCure Medical in a research note on Tuesday, October 25th. They set a "buy" rating and a $3.00 target price for the company.
Get IceCure Medical alerts:IceCure Medical Trading Down 3.0 %
The company has a 50 day moving average of $1.26 and a 200 day moving average of $1.39. The company has a current ratio of 4.22, a quick ratio of 3.58 and a debt-to-equity ratio of 0.03. The firm has a market cap of $59.31 million, a price-to-earnings ratio of -2.89 and a beta of -0.22.
IceCure Medical (NASDAQ:ICCM – Get Rating) last released its earnings results on Monday, December 5th. The company reported ($0.11) earnings per share for the quarter. The firm had revenue of $0.63 million for the quarter. IceCure Medical had a negative return on equity of 77.00% and a negative net margin of 462.46%. As a group, research analysts anticipate that IceCure Medical Ltd will post -0.42 EPS for the current year.Institutional Inflows and Outflows
A hedge fund recently bought a new stake in IceCure Medical stock. JPMorgan Chase & Co. purchased a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,240 shares of the company's stock, valued at approximately $78,000.
About IceCure Medical
(Get Rating)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Featured Articles
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) shares fell 3% during mid-day trading on Monday . The company traded as low as $1.30 and last traded at $1.30. 137,650 shares traded hands during trading, a decline of 76% from the average session volume of 566,353 shares. The stock had previously closed at $1.34.
ICECure 醫療有限公司（NASDAQ：ICCM-獲得評級）在周一的中午交易期間，股票下跌了 3％。該公司的交易價格低至 1.30 美元，最後交易價為 1.30 美元。137,650 股在交易過程中交易雙手，較 566,353 股的平均交易量下跌 76%。該股票之前已收盤 1.34 美元。
Analyst Ratings Changes
分析師等級變更
Separately, Maxim Group began coverage on IceCure Medical in a research note on Tuesday, October 25th. They set a "buy" rating and a $3.00 target price for the company.
另外，美心集團於 10 月 25 日（星期二）在一份研究報告中開始對 iCure 醫療的報導。他們為公司設定了「購買」評級和 3.00 美元的目標價格。
IceCure Medical Trading Down 3.0 %
iCure 醫療交易下跌 3.0%
The company has a 50 day moving average of $1.26 and a 200 day moving average of $1.39. The company has a current ratio of 4.22, a quick ratio of 3.58 and a debt-to-equity ratio of 0.03. The firm has a market cap of $59.31 million, a price-to-earnings ratio of -2.89 and a beta of -0.22.
該公司的 50 天移動平均線為 1.26 美元，200 日移動平均線為 1.39 美元。該公司的流動比率為 4.22，快速比率為 3.58，債務與權益比率為 0.03。該公司的市值為 5,931 萬美元，價格與收益比為 -2.89，測試版為 -0.22。
Institutional Inflows and Outflows
機構流入和流出
A hedge fund recently bought a new stake in IceCure Medical stock. JPMorgan Chase & Co. purchased a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,240 shares of the company's stock, valued at approximately $78,000.
對沖基金最近買入了 iCure 醫療股票的新股份。根據最近向美國證券交易委員會（SEC）提交的 13F 表格，摩根大通公司在第二季度購買了 iCure 醫療有限公司（NASDAQ：ICCM-獲得評級）的新股份。機構投資者購買了該公司股票的 7,240 股，價值約為 78,000 美元。
About IceCure Medical
關於「智健醫療」
(Get Rating)
(取得評分)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
iCure 醫療有限公司是一家醫療器械公司，從事人體腫瘤冷凍（冷凍）醫療器械的研究，開發和商業化。它提供 ProSense 系統，這是一種用於治療乳腺腫瘤的冷凍消融解決方案。該公司成立於 2006 年，總部設在撒利亞, 以色列.
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 免費獲取有關 ICURE 醫療（ICCM）的研究報告
- 為什麼黃金現在可以成為您的投資組合中閃閃發光的補充
- SoFi 技術打破收益，但要小心美聯儲決定
- 購買高露潔棕櫚樹的浸
- 馬倫汽車在招聘狂歡, 這可能意味著什麼?
- 數位互聯提出其收益指引
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 iCure 醫療日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 iCure 醫療及相關公司的最新新聞和分析師評級的簡明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧